Long-term clinical effect of the CCLG-ALL2008 regimen in treatment of childhood acute lymphoblastic leukemia with different molecular biological features.
- Author:
Xiao-Juan CHEN
1
,
2
;
Yao ZOU
;
Xiao-Ming LIU
;
Wen-Yu YANG
;
Ye GUO
;
Min RUAN
;
Fang LIU
;
Yu-Mei CHEN
;
Li ZHANG
;
Shu-Chun WANG
;
Xiao-Fan ZHU
Author Information
1. Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin 300020, China. xfzhu1981@
2. com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Child;
Child, Preschool;
Disease-Free Survival;
Female;
Fusion Proteins, bcr-abl;
Humans;
Infant;
Male;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
drug therapy;
Prognosis;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(9):890-893
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the long-term clinical effect of the CCLG-ALL2008 regimen in the treatment of children newly diagnosed with acute lymphoblastic leukemia (ALL) with different molecular biological features.
METHODS:A total of 940 children who were newly diagnosed with ALL were enrolled in this study. The children were treated with the CCLG-ALL2008 regimen. A retrospective analysis was performed for the long-term outcome of ALL children with different molecular biological features.
RESULTS:Among the 940 children with ALL, there were 570 boys and 370 girls, with a median age of onset of 5 years (range 1-15 years) and a median follow-up time of 65 months (range 3-123 months). The complete response (CR) rate was 96.7%, the predicted 10-year overall survival (OS) rate was 76.5%±1.5%, and the event-free survival (EFS) rate was 62.6%±3.0%. After CR was achieved after treatment, the overall recurrence rate was 21.9%. The children with positive ETV6-RUNX1 had the lowest recurrence rate and were prone to late recurrence, and those with positive MLL rearrangement had the highest recurrence rate and were prone to early recurrence. The children with positive ETV6-RUNX1 had a significantly higher predicted 10-year OS rate than those with positive TCF3-PBX1, BCR-ABL, or MLL rearrangement and those without molecular biological features (P<0.05). The children with positive ETV6-RUNX1 had a significantly higher predicted 10-year EFS rate than those with positive BCR-ABL or MLL rearrangement (P<0.05).
CONCLUSIONS:Molecular biological features may affect the long-term prognosis of children with ALL, and positive MLL rearrangement and BCR-ABL fusion gene are indicators of poor prognosis. Children with positive ETV6-RUNX1 fusion gene have the highest long-term survival rate.
